Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2013

View Archived Issues

Combinatorial strategies to enhance antitumor efficacy of monoclonal antibodies

Functional polymorphism associated with a predisposition towards allergic asthma reported

Serum miRNAs as markers of early gastric cancer risk

Bayer begins new collaboration with Seattle Genetics

RegeneRx reports results from phase II RGN-137 trial in epidermolysis bullosa

Myriad Genetics to conduct BRCA testing for Tesaro's niraparib studies

Boston College patents new PDE11A inhibitors

CytRx reaches target enrollment in phase IIb aldoxorubicin trial

Discovery of ROR-gamma inverse agonists for the treatment of Th17-mediated autoimmune diseases

Prima BioMed to begin three phase II trials of CVac

Cytokinetics and Astellas form skeletal muscle activator collaboration

Nanobiotix to develop NBTX-IV together with the NCI

Preliminary results from phase II trial of DN24-02 in urothelial cancer

Mesoblast receives approval for trial of mesenchymal precursor cells

NICE recommends dapagliflozin in certain patients with type 2 diabetes

Zealand Pharma presents ZP-GA-1, a new glucagon analogue

Findings link FOXJ1 gene with Barrett's esophagus

Celgene presents new protein kinase inhibitors

Boehringer Ingelheim designs novel mGlu5 receptor modulators

Chiesi Farmaceutici divulges novel MAPK 14 inhibitors

QRxPharma provides update on MoxDuo NDA review

Verastem begins phase I trial of VS-4718 in advanced cancer

Phase I study of MORAb-066 commences

Vivus obtains European approval for avanafil

FDA grants fast track designation to Genervon's GM-604 in ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...